1,423
Views
7
CrossRef citations to date
0
Altmetric
Original Article

The therapeutic potential of royal jelly in benign prostatic hyperplasia. Comparison with contemporary literature

, , , &
Pages 192-196 | Received 27 Nov 2015, Accepted 19 Mar 2016, Published online: 05 Apr 2016
 

Abstract

The aim of this study is to establish the scientific benefit of royal jelly (RJ) on prostatic-specific antigen (PSA), post-void residual (PVR) volume and International Prostate Symptom Score (IPSS) in benign prostatic hyperplasia. For the study, a group of 40 men were administered 38 mg of RJ over a period of three months, their PSA values, prostate volumes and the volumes of their transitory prostate zones, PVR and IPPS values were measured at the end of the first month, and at the end of the third month. The results of this study confirm the potential of RJ in reducing PSA scores and improving IPSS values. Since the use of RJ did not lead to any significant reduction in PVR, prostate volume, or to any involution of the transitory zone, it appears that it may only affect the blood marker of prostatic hyperplasia and to improve quality-of-life (QoL) in those patients. Overall, in comparison to phytotherapy and conventional therapy, RJ had similar positive effects on QoL in patients with BPH, however it exhibited markedly better effects on reducing PSA levels in blood. The therapeutical use of RJ exhibited no side effects.

Declaration of interest

No part of this paper has been presented, published, or submitted for publication elsewhere in this or in any other language.

This clinical study was conducted in accordance with the principles laid down in the WMA Declaration of Helsinki along with the strict respect of patient’s rights and clinical study protocol. Patient confidentiality and data security is guaranteed.

Authors did not have any support in funding of the paper. The authors of this paper hereby declare that have not received nor shall receive any financial benefits from publishing the paper, neither have they received any financial incentive from a third party. We, the author and co-authors, hereby solemnly declare that we are not in any situation which could give rise to a conflict of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.